Biosimilar key issues
A range of important issues impact the procurement and uptake of biosimilar medicines. In this section, we look in detail at some of the key areas of engagement which the British Biosimilars Association focuses on. We engage with a variety of stakeholders from parliamentary representatives and government departments through to NHS England, the MHRA, NICE and the EU.
Growing the market
In recent years, the uptake of biosimilar medicines in the UK has rapidly increased, driven by government engagement and policies focused on developing the market. We have worked closely with relevant bodies to drive awareness and use of these important medicines, which are saving the NHS significant sums of money while increasing patient access.
As the market develops further, it is important that policy and regulation keep pace with the commercial realities facing manufacturers.
The government has committed to making the UK a 'world-class launch destination' for biosimilars. We will work closely with supply chain colleagues to ensure that this commitment translates into tangible improvements.
Latest industry news
Partnership will revive inactive licences to solve critical medicines shortages
By Jeremy Durrant